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1. Introduction
1.1. A connective tissue
Bone is a highly specialized form of connective tissue that is nature’s provision for an internal
support system in all higher vertebrates. It is a complex living tissue in which the extracellular
matrix (ECM) is mineralized, conferring marked rigidity and strength to the skeleton while
still maintaining some degree of elasticity. In addition to its supportive and protective organic
ions, it actively participates in maintaining calcium homeostasis in the body.
Bone is composed of an organic matrix that is strengthened by deposits of calcium salts. Type
I collagen constitutes approximately 95% of the organic matrix; the remaining 5% is composed
of proteoglycans and numerous noncollagenous proteins. The crystalline salts deposited in
the organic matrix of bone under cellular control are primarily calcium and phosphate in the
form of hydroxyapatite (HA).
Morphologically there are two forms of bone: cortical (compact bone) and cancellous (spongy
bone). In cortical bone, densely packed collagen fibrils form concentric lamellae, and the fibrils
in adjacent lamellae run in perpendicular planes as in plywood. Cancellous bone has a loosely
organized, porous matrix. The differences between cortical and cancellous bone are both
structural and functional. Differences in the structural arrangements of the two types are
related to their primary functions: cortical bone provides the mechanical and protective
functions and cancellous bone provides the metabolic functions.
© 2013 Andrades et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.2. Bone cell structure and function
Bone is composed of four different cell types (Fig. 1). Osteoblasts, osteoclasts, and bone lining
cells are present on bone surfaces, whereas osteocytes permeate the mineralized interior.
Osteoblasts, osteocytes, and bone lining cells originate from local osteoprogenitor cells,
whereas osteoclasts arise from the fusion of mononuclear precursors, which originate in the
various hemopoietic tissues.
Figure 1. The origins and locations of bone cells. Taken from Academic Press Inc., with permission
Osteoblasts are the fully differentiated cells responsible for the production of the bone matrix.
Portions of four osteoblasts are shown in Figure 2. An osteoblast is a typical protein-producing
cell with a prominent Golgi apparatus and well-developed rough endoplasmic reticulum. It
secretes the type I collagen and the noncollagenous proteins of the bone matrix.
The staggered overlap of the individual collagen molecules provides the characteristic pe‐
riodicity of type I collagen in bone matrix. Numerous noncollagenous proteins have been
isolated from bone matrix (Sandberg, 1991) but to date there is no consensus for a defini‐
tive function of  any of  them. Osteoblasts  regulate the mineralization of bone matrix,  al‐
though the mechanism(s) is not completely understood. In woven bone, mineralization is
initiated away from the  cell  surface  in  matrix  vesicles  that  bud from the  plasma mem‐
brane of osteoblasts. This is similar to the well-documented role of matrix vesicles in car‐
tilage  mineralization  (Hohling  et  al.,  1978).  In  lamellar  bone,  the  mechanism  of
mineralization appears to be different.  Mineralization begins in the hole region between
overlapped collagen molecules where there are few, in any, matrix vesicles (Landis et al.,
1993) and appears to be initiated by components of the collagen molecule itself or noncol‐
lagenous proteins at this site.  Whatever the mechanisms of mineralization, collagen is at
least a template for its initiation and propagation and there is always a layer of unminer‐
alized bone matrix (osteoid) of the surface under osteoblasts. Matrix deposition is usually
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polarized toward the bone surface, but periodically becomes generalized, surrounding the
osteoblast  and producing the  next  layer  of  osteocytes.  Deposition of  mineral  makes  the
matrix impermeable and to ensure a metabolic lifeline, osteocytes establish numerous cy‐
toplasmic connections with adjacent cells before mineralization.
The osteocyte is a mature osteoblast within the bone matrix and is responsible for its mainte‐
nance (Buckwalter et al., 1995). These cells have the capacity not only to synthesize, but also
to resorb matrix to a limited extent. Each osteocyte occupies a space, or lacunae, within the
matrix and extends filopodial processes through canaliculi in the matrix to contact processes
of adjacent cells by means of gap junctions. Because diffusion of nutrients and metabolites
through the mineralized matrix is limited, filopodial connections permit communication
between neighbouring osteocytes, internal and external surfaces of bone and with the blood
vessels traversing the matrix. The functional capacities of osteocytes can be easily ascertained
from their structure.
Bone lining cells are flat, elongated, inactive cells that cover bone surfaces that are undergoing
neither bone formation nor resorption. Because these cells are inactive, they have few cyto‐
plasmic organelles. Little is known regarding the function of these cells; however, it has been
speculated that bone lining cells can be precursors for osteoblasts.
Osteoclasts are large, multinucleated cells which resorb bone. When active, osteoclasts rest
directly on the bone surface and have two plasma membrane specializations: a ruffled border
and a clear zone. The ruffled border is the central, highly infolded area of the plasma membrane
where bone resorption takes place. The clear zone is a microfilament-rich, organelle-free area
Figure 2. Transmision electron micrograph of osteoblasts (numbered) on a bone surface in which the collagenous ma‐
trix has been deposited in two layers (A and B) at right angles to each other. The Golgi apparatus (G) and rough endo‐
plasmic reticulum (r) are prominent cytoplasmic organelles in osteoblasts. (Original magnification x2800, bar 0.1 µm).
Taken from Academic Press Inc., with permission
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of the plasma membrane that surrounds the ruffled border and serves as the point of attach‐
ment of the osteoclast to the underlying bone matrix. Active osteoclasts exhibit a characteristic
polarity. Nuclei are typically located in the part of the cell most removed from the bone surface
and are interconnected by cytoskeletal proteins (Watanabe et al., 1995). Osteoclasts contain
multiple circumnuclear Golgi stacks, a high density of mitochondria, and abundant lysosomal
vesicles that arise from the Golgi and cluster near the ruffled border.
When a fracture occurs, a set of signals is triggered. These are both local signals and systemic
ones; some of these signals are mediated by neuronal impulses (Nordsletten et al., 1994), by
the haematoma at the site of the fracture and by the trauma caused to the tissues surrounding
the fracture (Einhorn, 1998). These signals can be divided into two interactive and inter‐
changeable categories: inflammatory signals and bone building signals. These factors mitigate
the migration of phagocytotic cells to the area of the fracture, removing the necrotic tissue and
propagating the in-growth of new blood vessels to the site of the fracture, thus providing
nutrients and cells to the fracture site and starting the healing cascade. If at the end of the
healing process osteo-integration (of the new bone together with the native bone) is not
achieved, even with the best type of scaffolds, the chances of long-term success are dismal
(Avila et al., 2009).
2. Bone tissue engineering
2.1. The basic concepts
Today great hope is set on Regenerative Medicine in all medical fields and, of course, it has
developed to be of interest in orthopedics, being bone defects one of the main focus. In the last
two decades, Regenerative Medicine approaches have been extensively studied to improve
bone healing, or even generate functional bone tissue to substitute lost bone in orthopedics,
neurosurgery, and dentistry. These types of studies include two different strategies of cell-
based therapy: in the first approach, called Cell Therapy, cells are applied to substitute
damaged cells within a tissue to reconstitute its integrity and function. The second approach,
called Tissue Engineering, is more complex and encompasses three approaches: bioactive
molecules (growth factors (GFs), cytokines, ECM compounds and hormones) that encourage
tissue induction; cells and cell substitutes that will respond to the signals; the seeding of cells
into three dimensional matrices, with specific adhesion properties and degradation rates, to
compose a tissue-like construct to substitute lost parts of the tissue, or even organs; and a good
nutritious support (angiogenesis) (Fig. 3).
Stem cells (SCs) are of particular interest in Regenerative Medicine, since they inhere several
unique characteristics that distinguish them from other cell types. SCs represent unspecialized
cells, which have the ability to differentiate into cells of all three germ layers, different adult
cell types, and represent the only cell type which has the ability to renew itself indefinitely. It
is important to distinguish embryonic stem cells (ESCs), which are truly pluripotent from
multipotent adult stem cells and only found in early developmental stages of the organism.
The successful dedifferentiation of somatic cells into a pluripotent ESC-like status by trans‐
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fection with four embryonic transcription factors, the so-called induced pluripotent stem cells
(iPS cells), provide the possibility of autologous therapy with pluripotent and easily accessible
cells in the future. Beside the great potential this technique undoubtedly represents, it bears
some essential safety problems which are currently far from being solved. In contrast, a variety
of multipotent adult SCs exists in assumedly all tissues of the organism. They are responsible
for maintaining the integrity of the tissue they reside in. Usually, these adult SCs show limited
differentiation potential to tissues of one germ layer.
Bone regeneration is a physiological process which can be observed in healing fracture and
continuous remodeling along by adult life. Bone holds the most regenerative ability of human
tissues contained on the mayor source of osteogenic cells capable for forming bones, the bone
marrow (BM). However, a loss considerable amount of bone due to any anomalies such as
severe trauma, skeletal deformations, bone tumor resection or periprosthetic osteolysis can
obstruct this capacity. Nevertheless, the capacity of proliferation and differentiation of BMSCs,
as well as cells concentration, are reduced with the increase of the age of the patient. Many in
vitro studies were performed to investigate applicability of different SC types for bone
regeneration. Here, promising capacity for differentiating towards bone cells, enhancing bone
healing and vascularization could be proven for ESCs and different adult mesenchymal stem
cells (MSCs). However, due to the ethical and safety concerns, which currently forbid appli‐
cations of ESCs or iPS cells in patients, we will focus on adult stem cells for therapeutic
Figure 3. The two strategies of stem cell application in Regenerative Medicine. Stem cells are either isolated from the
patient (autologous transplantation) or from other donors (allogenous transplantation). The cells are expanden in vi‐
tro and either applied directly to the patient to substitute lost cells (Cell Therapy), or seeded into 3 dimensional scaf‐
folds (Tissue Engineering) and differentiated into the demanded cell type. The composed artificial tissue construct is
subsequently implanted into patients’ tissue defect. Taken from A. Schmitt et al. 2012, with permission
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applications. Therefore, MSCs presently seem to be the most promising candidates for bone
regeneration, due to their excellent osteogenic differentiation capacity. They can be isolated
from a number of adult mesenchymal tissues, among others, umbilical cord blood, peripheral
blood, placenta, synovial fluid, adipose tissue, skeletal muscle or BM, as mentioned, where
they contribute to normal tissue turnover and repair. Recently, the multitude of cell surface
markers used in various studies has been limited to a marker panel representing, in addition
to plastic adherence and differentiation capacity, the minimal criteria for the identification of
MSCs. The molecular mechanisms of human MSCs regulation and the importance of specific
GFs during the different stages of osteogenic differentiation, as well as the secreted signaling
proteins known as Wnts, implicated in various differentiation programs including osteogen‐
esis, are subjects of intensive research right now. Several studies have demonstrated improved
results of MSCs therapy with genetically modified cells which produce osteogenic and
angiogenic GFs in a local delivery of therapy strategy for bone healing. Also, there is recent
information about the use of endothelial progenitor cells (EPCs) that improves the treatment
of fracture and bone regeneration.
Besides their unique ability to differentiate into different cell types, MSCs secrete a variety of
cytokines, showing anti-inflammatory activity and create an anabolic microenvironment.
Furthermore, direct cell-cell contact immunomodulation has also been shown. On one hand,
they indirectly influence tissue regeneration by secretion of soluble factors. On the other hand,
they are able to modulate the inflammatory response. The differentiation potential of MSCs in
bone engineering has been extensively studied in vitro and in vivo. By first time, Urist (1965),
and Reddi and Huggins (1972) showed the capacity of a molecule, called bone morphogenetic
protein (BMP), with potent osteoinductive properties in healing fractures and bone regenera‐
tion. Their experiments demonstrated the presence of osteoinductive cytokines in bone matrix
that have abilities to induce MSCs differentiation into osteoblasts. The GFs, also including
transforming growth factor-beta (TGF-β), fibroblast growth factor (FGF), platelet derived
growth factor (PDGF), vascular endothelial growth factor (VEGF) or insulin-like growth factor
(IGF), among others, are delivered of paracrine or autocrine manner, generating a chemotaxis
process toward MSCs by recruitment, which induce their differentiation.
Extracellular matrix (ECM) is the native scaffold in most tissues. Besides the direct injection in
the surrounding tissue, biomaterials are frequently used as carriers for cells, bioactive mole‐
cules and drugs. These materials have to be immune-compatible and nontoxic, whereas the
bio-degradation process must neither release toxic substances nor tissue-toxic concentrations
of degradation products. Scaffolds must be of three-dimensional structures, with great
influence on cell growth and differentiation, and must be highly porous with interconnected
pores of a diameter of at least 100 µm to allow ingrowth of cells and vessels. Despite the tissue
engineering of bone, for which various inorganic materials, such as HA, calcium phosphate,
calcium carbonate (due to their similarity to bone mineral, as well as their inherent biocom‐
patibility and osteoconductivity), or glasses was tested, mainly organic biomaterials have been
investigated for scaffold production. These are either naturally derived, for example, collagen,
fibrin, agarose, alginate, gelatin, silk or hyaluronic acid; or produced synthetically, such as
polyhydroxyacids. Since natural bone consists of an ECM with nanosized apatitic minerals
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and collagen fibers that support bone cell functions, it is of interest to manufacture a synthetic
biomimetic scaffold to i) contain nano-apatite crystals, together with fibers to form a matrix
that supports cell attachment; ii) have mechanical properties similar to those of bone; and iii)
encapsulate and support cells for osteogenic differentiation. Different methods have been
employed in the fabrication of nanomaterials for bone engineering, such as the principle of
electrospinning, that produce a variety of synthetic biomaterials, or the novel thermally
induced phase separation (TIPS) technique to fabricate nanofibers to mimic natural collagen
fibers. Rapid developments in this field of nanotechnology will be a key for many clinical
benefits in the field of bone tissue engineering. The main advantage is that several novel
biomaterials can be fabricated into nanostructures that closely mimic the bone in structure and
composition. The optimization in the surface features of scaffolds has strongly improved cell
behavior in terms of adhesion, proliferation, differentiation and tissue formation in three
dimensions.
3. Stem cells as source
The popularity of SCs in the clinical arena has significantly increases, given the rapid im‐
provement in our understanding of their biology. Classically, SCs are defined by their capacity
to retain an undifferentiated state for a prolonged period while retaining the potential to
differentiate along one lineage (unipotent), multiple lineages (multipotent), or into all three
germ layers (pluripotent) (Young, 2003). These cells can be broadly categorized into two major
classes: embryonic and adult SCs.
Embrionic stem cells (ESCs), isolated from the inner cell mass of the blastocyst, are pluripotent
cells with the potential of differentiating into tissues from all three germ layers (Fig. 4) (Buehr
et al., 2008).
While ESCs have significant regeneration capacity, their clinical application has been limited
as a result of multiple factors including: 1) a propensity to form teratomas, 2) ethical concerns
with isolation, 3) rejection by the host immune system after transplantation, and 4) the use of
a feeder layer to retain an undifferentiated state in vitro (Cho et al., 2010). Recently discovered,
another source of pluripotent SCs are induced pluripotent stem (iPS) cells, derived from
somatic cells treated with few defined factors (Hamilton et al., 2009). While iPS cell-based
therapy has the potential to revolutionize the field of Regenerative Medicine, many obstacles
must be overcome before their clinical application can be realized (Lengner et al., 2010).
3.1. Mesenchymal stem cells as candidates
Furthermore, naturally occurring adult SCs have also been identified and categorized into their
hematopoietic stem cells (HSCs), a source of various hematopoietic cell lineages, and nonhe‐
matopietic SCs, which can give rise to cells of mesenchymal origin (de Barros et al., 2010). Many
reports have suggested that these nonhematopoietic SCs, also known as mesenchymal stem
cells (MSCs), can be isolated from a wide variety of adult tissues such as blood, adipose, skin,
mandibule, trabecular bone, fetal blood, liver, lung and even the umbilical cord and placenta
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(Steinhardt et al., 2008). The wide range of sources, methods, and acronyms are standardized
by the International Society for Cellular Therapy in 2005.
Upon harvest, these cells can be expanded in vitro with high efficiency without sacrificing
differentiation capacity (Kassem, et al., 2004). While these multipotent progenitor cells share
many similar characteristics, they can be differentiated based on their expression profile and
differentiation propensity along various lineages (Wagner et al., 2005). Amongst the various
sources, MSCs isolated from the BM are considered to have the greatest potential for multili‐
neage differentiation and have been the most characterized (Kuznetsov et al., 2009).
MSCs were initially described by Friedenstein and colleagues more than 40 years ago as
adherent cells, with a fibroblast-like appearance capable of differentiating in vitro into
osteoblasts, chondroblasts, adipocytes, and tenocytes (Friedenstein et al., 1968; Alonso et al.,
2008; Prockop et al., 2009; Andrades et al., in press (a). Unlike ESCs, MSCs provide the
flexibility of autologous transplantation, circumventing ethical concerns or immunological
rejection (Igura et al., 2004). These cells also play a sentinel role in proliferation and differen‐
tiation of hematopoietic cells (Briquet et al., 2010). Mankani et al. illustrated that the formation
of both hematopoiesis and mature bone organ is correlated with the high local density of MSCs
(Mankani et al., 2007). Additionally, MSCs are considered to be immune privileged and have
the capacity for allogenic transplantation a property has been used in the clinical setting for
the treatment of various autoimmune diseases (Le Blanc et al., 2008). While many studies have
suggested that MSCs are immunoprivileged and do not undergo rejection, others have cast
doubt on this notion, showing that in certain scenarios, MSCs induce immune rejection (Nauta
Figure 4. Origin of the different types of stem cells available. Derivation of embryonic stem cells (ESCs), embryonic
germ cells (EGCs) and adult stem cells (SCs). Taken from M.E. Arias and R. Felmer 2009, with permission
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et al., 2006) (Fig. 5). More investigations should be conducted to provide further insight into
the specific interaction between these progenitor cells and the host immune system.
Figure 5. Stem cells participate in tissue regeneration in different ways. They directly differentiate into tissue-specific
cells and thus substitute damaged or lost cells (A). They indirectly influence tissue regeneration by secretion of soluble
factors. Here they promote vascularization, cell proliferation, differentiation within the tissue (B) and modulate inflam‐
matory processes (C). Taken from A. Schmitt et al. 2012, with permission
Considerable effort has been put forth to identify specific surface markers that characterize
MSCs, yet disagreement within the literature has prevented the creation of definitive stand‐
ards. The minimal criteria identified by the International Society for Cellular Therapy for
identifying MSCs requires the cells: 1) to be plastic adherent while maintained in cell culture;
2) to express CD73, CD90, and CD105, and lack expression of CD11b, CD14, CD19, CD34,
CD45, CD79-alpha, and HLA-DR; and 3) to differentiate into osteoblasts, adipocytes, and
chondroblasts in vitro (Dominici et al., 2006; Claros et al., 2008; 2012). Additional studies have
also suggested that CD146 is considered an important marker of BM progenitor cells
(Sorrentino et al., 2008). These guidelines were set in place to enable a unified approach for
comparison amongst different studies.
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BM is generally considered milieu plentiful for various cell types, collectively referred to as
stromal cells. Amongst these, the multipotent subset of MSCs comprises a small fraction (<0.01)
(Dazzi et al., 2006), yet despite their small numbers, the relative ease with which MSCs can be
harvested has propelled their experimental use. Researchers have pioneered the creation of
stable animal models aimed at mimicking human conditions to study the therapeutic capacity
of these BM-derived cells (Kadiyala et al., 1997). Because of their ubiquity, tolerance of
expansion, paracrine capabilities, and multipotency, the potential for clinical applications of
MSCs in the orthopaedic realm is countless (Becerra et al., 2011).
The first problem that arises when Cell Therapy methods are used to rebuild bone tissue is
how to obtain a sufficiently large number of osteocompetent cells for the intervention to be
successful. Hence, the idea of using SCs, which are self-renewing and differentiate into various
tissues, surfaced.
4. Direction by growth factors
Growth factors (GFs) serve a critical role in Regenerative Medicine, facilitating tissue growth
in vitro and repair in vivo. In the case of skeletal tissues, they are being using to regulate
chemotaxis, proliferation, and differentiation of MSCs. Also, selected hormones, cytokines,
and nutrients are potentially useful in controlling MSCs growth.
A GF is a signaling biomolecule, commonly polypeptide, that is not a nutrient. Typically they
act as signaling molecules via binding to specific receptors on the same cells that secrete the
factors (autocrine signaling) or on neighboring cells (paracrine signaling). The binding of the
receptor initiates a cascade of cellular reactions, often involving the activation of specific gene
transcription. These cellular activities lead to alterations in cell proliferation, differentiation,
maturation, and production of other GFs and ECM, all of which result in the formation of
specific tissues. Unlike hormones, which act on cells distant from the source (endocrine
signaling), GFs have a local (nonsystemic) effect and are often secreted at low concentrations
(Fig. 6).
4.1. Transforming growth factor-beta (TGF-β) superfamily
Members of this superfamily, as bone BMPs, growth differentiation factors (GDFs) and TGF-
βs, are involved in the different stages of repair bone (intramembranous and endochondral
bone ossification) during bone repair (Gerstenfeld et al., 2003).
4.1.1. Transforming growth factor-beta (TGF-β)
The term transforming growth factor beta is applied to the superfamily of length well-known
growth factors involved generally with connective tissue repair and bone regeneration present
in many types of tissue (Lieberman et al., 2002). TGF-β exists as five isoforms, three of them
have received the most attention regarding fracture repair and proliferation of MSCs (TGF-β1,
TGF-β2, TGF-β3), although TGF-β3 has the most pronounced effect on increases proliferation
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of MSCs and chondrogenesis (Weiss et al., 2010). All TGF-β members superfamily are synthe‐
sized as large precursors which are proteolytically cleaved to yield mature protein dimers
(Massague et al., 1994). TGF-β signaling that involves two receptor types, TGF-β receptor type
I and type II, occurs when factors from the family bind a type II serine/threonine kinase
receptor, recruiting another similar transmembrane protein (receptor I). Receptor I phosphor‐
ylates the primary intracellular superfamily signal effector molecules, SMADs, causing their
translocation into the nucleus and specific gene transcription (Valcourt et al., 2002). TGF-β and
members of this growth factor family can also signal via the mitogen activated protein tyrosine
kinase (MAPK), Rho GTPase and phosphoinositide 3kinase (PI3K) pathways (Zhang, 2009).
Like PDGF, they are synthesized and found in platelets and macrophages, as well as MSCs
and some other cell types (Barnes et al., 1999), acting as paracrine and autocrine fashion (Fig.
7). TGF-βs inhibit osteoclast formation and bone resorption, thus favoring bone formation over
resorption by two different mechanisms (Mohan & Baylink, 1991). The TGF-β activates
fibroblasts and preosteoblasts to increase their numbers, as well as promoting their differen‐
tiation toward mature functioning osteoblasts. It influences the osteoblasts to lay down bone
matrix and the fibroblast to lay down collagen matrix to support capillary growth (Marx et al.,
1996). They also play a role in osteogenesis, its actions are diverse and it is thought to influence
the activity of BMPs (Salgado et al., 2004). TGF-β1 plays a pivotal role in the process and site
of fracture healing where appears elevated levels in humans, as well as in other mammals, as
it enhances the proliferation and differentiation of MSCs and is chemotaxis on bone cells
(Sarahrudi et al., 2011).
Figure 6. Growth factor regulation of BM-derived MSCs differentiation. Among the classes of bioactive factors, such
as matrix ligand, mechanical stimulation, and cell shape, GFs exert strong effects on the regulation of the lineage dif‐
ferentiation of MSCs. Boxed GFs and hormones are used to control bone differentiation in vitro. Factors under the ar‐
row have been implicated in promoting regulation differentiation. Pictures represent two histological sections,
stained with Sirius red and observed under light (left, femur segmental resection) and polarized (right, profile of a hy‐
droxyapatite implant) microscopes. New bone tissue appears in red. Results obtained in LABRET-UMA
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Figure 7. The signal cascade inside the cell after the receptor binding of GFs involves in bone repair. Taken and modi‐
fied from L. Barnes et al. 1999, and Rodrigues et al. 2010, with permission
Also, our group have demonstrated that osteogenic precursor cells can be selected from a
mixed population of BM MSCs by virtue of their distinctive survival responses in the presence
of a recombinant human TGF-β1 fusion protein (Andrades et al., 1999a; 1999b; Andrades and
Becerra, 2002a; Andrades et al., 2003; Becerra et al., 2006; Claros et al., in press), engineered to
contain an auxiliary collagen binding domain (rhTGF-β1-F2) (Fig. 8), and further, that these
selected cells exhibit unique properties in the chodroosteogenic lineage that can ultimately be
utilized to therapeutic advantage
4.1.2. Bone morphogenetic proteins (BMPs)
The first BMP was identified by Urist (1965). He observed the ability from demineralized bone
matrix (DBM), to induce ectopic bone formation when implanted under the skin of rodents,
and showed that there was a recapitulation of all the events that taking place during skeletal
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development. In 1971, it was named as the responsible factors BMPs. More lately, others
searchers, as Reddi and Huggins (1972) demonstrated that these molecules are important
during development. Even present, at least many than 30 BMPs have been identified and BMP
´s functions have been studied by means of analysis of mutant genes and knockout experiments
in mice. Different BMPs, among others member of the TGF-βs superfamily, trigger a serine/
threonine kinasa cascade of events that induce the formation of cartilage and bone (Fig.7).
During fracture repair, BMPs are produced by MSCs, osteoblasts, and chondrocytes, and bind
to cells by direct interaction or are accumulated and subsequently delivered of ECM to promote
the bone generation. These proteins induce a cascade of cellular pathways that promote cell
growth, migration and differentiation of MSCs to repair the injury, stimulates angiogenesis,
as well as synthesis of ECM and play a regulatory role in tissue homeostasis (Reddi, 2001). The
different BMPs act in different temporal scale during bone repair. In studies of fracture healing,
BMP-2 mRNA expression showed maximal levels within 24 hrs of injury, suggesting that this
BMP plays a role in initiating the repair cascade. Other in vitro studies examining marrow
MSCs differentiation have shown that BMP-2 controls the expression of several other BMPs,
and when its activity is blocked, marrow MSCs fail to differentiate into osteoblasts (Edgar et
al., 2007).
BMP-3, BMP-4, BMP-7, and BMP-8 are expressed during bone repair, from days 14 to 21, when
the resorption of calcified cartilage and osteoblastic recruitment are most active, and bone
formation takes place. Our group has demonstrated that BMP-7 is capable of selecting a cell
population from BM which, in a three dimensional collagen type I gel, achieves skeletogenic
potential under in vitro and in vivo environments (Andrades et al., 2001; Andrades and Becerra,
2002b; Andrades et al., 2003). BMP-5 and BMP-6 and other members of the TGF-βs superfamily
are constitutively expressed from days 3-21 during fracture in mice, suggesting that they have
a regulatory effect on both intramembranous and endochondral ossification. BMP-2 to BMP-8
show high osteogenic potencial, however BMP-2, BMP-6, and BMP-9 may be the most potent
Figure 8. Schematic representation of the genetically engineered fusion construct, containing a histidine purification
tag, a protease site, an auxiliary von Willebrand Factor collagen binding domain. Recombinant hTGF-β1-F2 applied to
a bovine collagen matrix as vehicle and delivery system could be of advantage in promoting the survival, proliferation,
differentiation, and colony mineralization of the osteogenic precursor cell population. It plays a crucial role in early
stages of osteogenic commitment and differentiation. Results obtained in LABRET-UMA
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inducers of MSCs differentiation to osteoblasts, while the others, stimulate the maturation of
osteoblasts (Cheng et al., 2003).
The first BMP extracted in a highly purified recombinant form was BMP-2. In preclinical
models, BMP-2 has the ability to induce bone formation and heal bone defects and promote
the maturation and consolidation of regenerated bone. Recombinant human BMP-7 and BMP-2
are among the first growth factor based products available for clinical use to treat patients
afflicted with bone diseases. A large number of studies have been performed to determine
appropriate carriers for BMPs (Cheng et al., 2003).
In vitro cultures, MSCs and osteoblasts exhibit a high number of BMP receptors and synthesize
the BMP antagonist’s noggin, which are capable of blocking osteogenesis as MSCs differentiate
into osteoblasts. BMP antagonists are important in normal bone turnover and regulation. The
expression of the BMP antagonists, as noggin, which blocks BMP-2, BMP-4, and BMP-7
interaction with its receptor, also is modulated during bone repair (Balemans et al. 2002).
4.1.3. Wnt proteins
The Wnt pathway was initially identified as a proto-oncogene in mammary tumors that was
activated by integration of the mouse mammary virus (Nusse & Varmus, 1982). Since then, it
has been the subject of many studies. It knows Wnt proteins are secreted cysteine-rich
glycosylated family proteins to share a highly conserved pattern of 23–24 cysteine residues
and several asparagines-linked glycosylation sites (Li et al., 2006). In mature tissues, Wnt
pathway play a regulator role of osteogenesis and stem/progenitor cells self-renewal, it is
involved in bone formation, and also cellular adhesion and migration through their indirect
interactions with the cadherin pathway (Arnsdorf et al., 2009).
Wnt proteins are divided towars to activate one of two main signaling pathways that consist
of the Wnt1 class, also called Wnt/β-catenin or canonical Wnt pathway and Wnt5a class, Wnt/
Ca2+ or non-canonical pathway. Several lines of evidence have demonstrated the importance
of canonical Wnt signaling in promoting osteogenesis in vitro and in vivo (Chung et al., 2009).
Wnt signaling is a prime target for bone active drugs and the approaches include inhibition of
Wnt antagonist like Dkk1, sclerostin, and Sfrp1 with neutralizing antibodies and inhibition of
glycogen synthase kinase 3β (GSK-3β), which promotes phosphorylation and degradation of
β-catenin. Enhancement of Wnt signaling either by Wnt overexpression or deficiency of Wnt
antagonists (ten Dijke et al., 2008) is associated with increased bone formation in mice and
humans. Gain of function mutations of LRP5/6 that lead to impaired binding of Dkk-1
(Dickkopf-1 is a secreted Wnt antagonist that binds LRP5/6) to this Wnt coreceptor are
associated with increased bone mass (Boyden et al., 2002).
In spite of osteogenic inhibitory function of canonical Wnts, this pathway plays a positive role
in bone homeostasis in vivo (Liu et al., 2009). Canonical Wnt signaling in osteoblast differen‐
tiation is modulated by Runx2 and osterix transcription factors (Hill et al., 2005). Quarto et al.
(2010) have shown canonical Wnt signaling can either inhibit or promote osteogenic differen‐
tiation depending on the status of cell (cellular differentiation degree undifferentiated vs.
differentiated), the threshold levels of its activation (existence of a differential activation of
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canonical Wnt signaling between an undifferentiated MSC and osteoblast), and Wnt ligands
concentration showing in vitro and in vivo data correlated results for Wnt3a treatment of
calvarial defects created in juvenile mice where rise activation of canonical Wnt signaling
inhibited osteogenic differentiation of undifferentiated MSCs, whereas increased the miner‐
alization of differentiated osteoblasts.
4.2. Growth hormone and insulin-like growth factors (GH and IGF)
In clinic, the patients that present short stature are treated with the Growth Hormone (GH);
for this reason, many researcher study the effects of GH in the treatment for osteoporosis and
repair bone fracture. It is released by pituitary gland and travels through the circulation to the
liver, where target cells are stimulated to release IGF. There are two IGFs identified: IGF-I and
IGF-II. Various studies have shown that both IGF-I and IGF-II (Swolin et al., 1996;) are
delivered by osteoblasts, chondrocytes, endotelial cells, and bone matrix, and they are detected
by recruitment MSCs and bone cells in a paracrine/autocrine manner thanks to the presence
of six insulin growth factor-binding proteins (IGFBPs), which modulate their action by
intracellular tisone kinase cascade.
IGF-II is the most abundant GF in bone matrix. However, IGF-I is 4 to 7 times more potent in
synthesis of bone matrix (type I collagen and non-collagen matrix proteins) (Lind, 1996). IGF-
II acts on phase of endochondral bone formation and induces type I collagen production,
stimulates cartilage matrix synthesis, and cellular proliferation. Both factors have been
localized in bone studies of animals and humans with GH-deficient levels. The expression and
secretion of IGFBPs, IGF-I and IGF-II (Birnbaum et al., 1995) changes during in vitro MSCs
cultures. Prisell et al. (1993) showed that IGF-I mRNA was expressed during the MSCs
recruitment and proliferation; however IGF-II mRNA expression happened later, during
endochondral bone formation by osteoblasts and chondrocytes. IGF production is not only
under the control of GH, is also regulated by estrogen, PTH, cortisol (inhibits IGF-I synthesis),
local GFs and cytokines (Ohlsson et al., 1998). This abundant supply of IGFs is necessary to
promote bone formation, bone repair, and MSCs cell proliferation and differentiation.
4.3. Fibroblast growth factor (FGF)
FGF is a secreted glycoproteins family whose signals are implicated in wound healing and
angiogenesis, which influence in cellular proliferation, differentiation, migration, survival and
polarity transduced through their receptors (FGFR1, FGFR2, FGFR3 and FGFR4). These
receptors are constituted of extracellular immunoglobulin-like (Ig-like) domains and cyto‐
plasmic tyrosine kinase activity domain. FGF proliferation signals occur through the tyrosine
kinase cascade in various target cell types (Ng et al., 2008).
The various FGF receptors display varying affinities for each of the members of the FGF
family  and are  expressed  in  a  wide  variety  of  tissues  including  indeed,  bone.  As  with
many of  the tyrosine kinase receptors,  activation of  the intrinsic  tyrosine kinase activity
occurs through receptor dimerization in response to ligand binding. An additional com‐
plexity  may be added to  the  receptor-ligand association through the binding of  FGF li‐
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gand by either secreted or membrane-bound proteoglycans, heparin-like proteoglycans in
particular  because  their  high affinity  (Givol  & Yayon,  1992).  Nine members  of  the  FGF
family have been identified of which, the most abundant in human tissue are FGF-1 (acid
character) and FGF-2 (basic character) (Lieberman et al.,  2002). FGFs are important regu‐
lators of fracture repair expressed by MSCs, maturing chondrocytes and osteoblasts and
have  been  demonstrated  to  enhance  TGF-β  expression  in  osteoblastic  cells  (Bolander,
1998). They play a role in maintaining the balance between bone-forming cells and bone-
resorbing  cells  and  promote  angiogenesis.  Specifically,  FGF-2  not  only  maintains  MSCs
proliferation  potential,  it  also  retains  a  slight  osteogenic,  adipogenic  and  chondrogenic
differentiation potentials  through the  early  mitogenic  cycles;  eventually,  however,  all  of
the MSCs differentiate into the chondrogenic line (Yanada et al., 2006).
4.4. Platelet derived growth factor (PDGF)
PDGFs are potent mitogens of MSCs (Ng et al., 2008) which express all forms of the GF: PDGF-
A and PDGF-C at higher levels, and PDGF-B and PDGF-D at lower levels, such as both
receptors type PDGFRα and PDGFRβ through which PDGF signaling is transduced (Tokunaga
et al., 2008). PDGF is a dimeric molecule can exist either as a homodimeric (PDGF-AA, PDGF-
BB, etc) or a heterodimeric form (PDGF-AB) according to the relative levels of each subunit
generating a level of ligand complexity in cells in which both polypeptides are expressed. The
different PDGF isoforms exert their effect on target cells by binding with different specificity
to two structurally related protein tyrosine kinase receptors, denoted as the α-receptors and
β-receptors, which are autophosphorylate ligand bound (Tokunaga et al., 2008). Several
groups have found PDGF-BB to induce both proliferation and migration in MSCs (Fierro et
al., 2007). While PDGFRβ inhibits osteogenesis, however, PDGFRα has been observed to
induce osteogenesis. Akt signaling has been proposed to mediate both the suppression and
induction of osteogenesis by PDGFR signaling (Tokunaga et al., 2008).
These  molecules  acts  as  paracrine  manner  stimulating  mitogenesis  of  the  marrow  SCs
and endosteal osteoblasts transferred in grafts to increase their numbers by several orders
of magnitude. It also begins an angiogenesis of capillary budding into the graft by induc‐
ing endothelial cell mitosis and macrophage activator effect. It is known to emerge from
degranulating platelets at the time of injury. PDGF also increased hMSC proliferation like
Wnt (Liu et  al.,  2009).  PDGF recruits  MSCs and promotes  chemotaxis  and angiogenesis
(Salgado et al., 2004).
5. Biomaterials as support
Natural bone consists of an ECM with nanosized apatitic minerals and collagen fibers that
support bone cell functions. It is advantageous for a synthetic biomimetic scaffold to: (1)
contain nano-apatite crystals similar to those in bone, together with fibers to form a matrix that
supports cell attachment; (2) have mechanical properties similar to those of bone; and (3)
encapsulate and support cells for osteogenic differentiation and bone regeneration. The success
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in regenerating a damaged tissue using the tissue engineering approach depends on the
various types of interactions between the cells, scaffolds, and GFs. Besides, an understanding
of the phenomena of cell adhesion and, beyond, the function of the proteins involved in cell
adhesion on contact with the materials and the purpose depends of supramolecular assembly
(scaffolding) of biomimetic biomaterials such as collagens, proteoglycans, and cell adhesion
glycoproteins such as fibronectins and laminin.
Osteogenesis is highly dependent on the substrate carrier used, which has to provide a
favorable environment into which bone cells can migrate before proliferating, differentiating,
and depositing bone matrix (i.e., osteoconduction) (Ono et al., 1999). At the cell level, substrates
of this kind must have specific biochemical (molecular) properties, physicochemical charac‐
teristics (surface free energy, charge, hydrophobicity, and so on), and a specific geometric
conformation (they must be three dimensional and show interconnected porosity) (Jin, 2000).
From the biomaterial point of view, the scaffolds used for bone engineering purposes have to
meet a number of criteria, including (1) biocompatibility (nonimmunogenicity and nontoxic‐
ity); (2) resorbability (showing resorption rates commensurate with the bone formation rates);
(3) preferably radiolucency (to allow the new bone to be distinguished radiographycally from
the implant); (4) osteoconductivity; (5) mechanical properties to match those of the tissues at
the site of implantation; (6) easy to manufacture and sterilize; and they must be (7) easy to
handle in the operating theater, preferably without requiring any preparatory procedures (in
order to limit the risk of infection).
The bone substitute materials intended to replace the need for autologous or allogeneic bone,
consist of bioactive ceramics, bioactive glasses, biological or synthetic polymers, and compo‐
sites of these. Biological polymers, such as collagen and hyaluronic acid provide guidance to
cells that favors cell attachment and promotes chemotactic responses, but, a disadvantage is
immunogenicity for the potential risk of disease transmission. On the other hand, other
alternative is synthetic polymers such as polyfumarates, polylactic acid (PLA), polyglycolic
acid (PGA), copolymers of PLA and PGA (PLGA), and polycaprolactone. Nevertheless, there
are a wide range of bioactive inorganic materials similar in composition to the mineral phase
of bone, for example, tricalcium phosphate, HA, bioactive glasses, and their combinations; and
all of these can be tailored to deliver ions such as Si at levels capable of activating complex
gene transduction pathways, leading to enhanced cell differentiation and osteogenesis.
Hydrogels, such as polyethylene glycol or alginate-based, are to provide a three-dimensional
cellular microenvironment with high water content, this is suitable for cartilage regeneration.
Polyethylene glycol (PEG) hydrogels were investigated as encapsulation matrices for osteo‐
blasts to assess their applicability in promoting bone tissue engineering. Non-adhesive
hydrogels were modified with adhesive Arg-Gly-Asp (RGD) peptide sequences to facilitate
the adhesion, spreading, and, consequently, cytoskeletal organization of osteoblasts. Finally,
mineral deposits were seen in all hydrogels after 4 weeks of in vitro culture, but a significant
increase in mineralization was observed upon introduction of adhesive peptides throughout
the network. Potentially, the cell suspension could be injected into the body through a needle
and photopolymerized through the skin to provide a non-invasive technique to enhance bone
regeneration.
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Biomaterials such as polymers, ceramics, and metals are widely used in bone for regenerative
therapies, including in bone grafts and in Tissue Engineering as well as for temporary or
permanent implants to stabilize fractures (Navarro et al., 2008). In recent years, biomaterials
in general and bone-related implant materials in particular have been considerably refined,
with the objective of developing functionalized materials, so-called smart materials, containing
bioactive molecules to directly influence cell behaviour (Mieszawska and Kaplan, 2010). Rapid
developments in nanotechnology have yielded many clinical benefits, in particular in the field
of bone tissue engineering. The main advantage in that several novel biomaterials can be
fabricated into nanostructures that closely mimic the bone in structure and composition. The
optimization in the surface features of biomaterials has strongly improved cell behaviour in
terms of adhesion, proliferation, differentiation and tissue formation in three dimensions. In
this context, nanoparticles that are in the same size range as integral parts of natural bone, such
as HA crystals or cellular compartments, are promising candidates for local applications. In
bone, locally applied nanoparticles may be suitable for numerous potential uses with respect
to the improvement of tissue regeneration, the enhanced osseointegration of implants, and the
prevention of infections.
Increasingly refined nanoparticles are being developed for a wide range of applications (Fig.
9). These include cell labelling to broaden research possibilities as well as to improve and
noninvasively monitor cell therapy approaches (Bhirde et al., 2011; Andrades et al., in press
(b). Moreover, drug delivery systems with improved pharmacologic characteristics are being
developed. They promote enhanced therapeutic outcome by providing controlled release of
bioactive molecules, such as growth factors or anticancer drugs (Allen and Cullis, 2004). In
addition, gene therapy concepts with good prospects are required for future treatment options
based on intracellular manipulation (Evans, 2011).
The heterogeneous picture of research on the interactions of nanoparticles with MSCs makes
it difficult to draw general conclusions. However, it becomes clear that parameters such as
chemistry, size, and shape in some cases greatly affect the particle uptake behaviour of MSCs
as well as their natural differentiation potential. Different strategies for nanoparticle applica‐
Figure 9. Overview of nanoparticle applications in bone regeneration
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tion in bone (i.e., as cell-labeling agents and for drug or gene delivery) have great potential for
monitoring and supporting tissue regeneration.
6. Conclusion
Over the last decades we have advanced in many aspects of bone defects treatment. We have
good understanding of the components involved in the healing of bone. Osteoprogenitor cells
are necessary to replace the inserted scaffold and to create new bone tissue. These cells, MSCS,
can come from the periosteum, the BM, or from chemotaxis and blood vessels entering the
haematoma at the fracture site. Specific mechanical and biological stimulants cause the cells
to differentiate into osteoblasts, which are the bone forming cells (Fig. 10). However, in critical
size bone defects the natural migration of osteoprogenitor cells does not suffice for fracture
healing. In normal conditions MSCs are rare (one in 10 million cells) (Pittenger et al., 1999).
However, when a bone is broken, these cells, using special probing signals, roam in the blood
and settle in the fracture site, differentiate into bone cells and start to construct the callus. The
number of stem cells differs from person to person and is affected by age, sex and environ‐
mental factors.
Also, we have strived forward in defining different components of bone regeneration and have
achieved a good combination of biology and technology leading to solid and reproducible
answers to the in vitro and animal in vivo problem of bone defects. However, there is still one
more step to take (the human in vivo step). There are scant data with respect to this part of the
question, and in the next few years this field must undergo a transition, giving clinicians tools
to deal with these critical everyday problems. The solution will come from a collaborative work
of biologist, surgeons, engineers and chemists who possess the social understanding that there
has to be a limit to the cost that the patient (and the society) can bear for healing a fracture.
Figure 10. Bone fracture repair and regeneration is a question of balance among cells, growth factors and bioma‐
terials.
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Consequently, the search for the new bone regeneration strategies is therefore a key interna‐
tional priority fuelled by the debilitating pain associated with bone damage, and the increasing
medical and socioeconomic challenge of our aging population.
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